Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Hovione today announced that it plans to host and operate a commercial-scale continuous manufacturing facility as part of an agreement with Vertex Pharmaceuticals
C&EN, May 21, 2018
CheManager, 20 October 2020
Scientist Live, 12 May 2025
Hovione announces that the consolidated sales volume for the fiscal year ended 31st March 2005 amounted to US$81.4 million, representing a growth of 8% over the previous year.
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
Safety First, Quality Always: We are continuously improving the safety of our operations with the patient’s safety in mind.
Hovione, the specialist integrated CDMO, just announced an expansion of its nasal drug delivery capabilities with the addition of a family of innovative nasal powder delivery devices developed in partnership with IDC.
Google Chrome
Safari
Firefox
Edge